SCHEMBL961469

SCHEMBL961469

CC(=O)Oc1cccc(-c2nc(Cl)c3sccc3n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.44
ROCK2 O75116 1/20 0.43
ADORA2A P29274 2/20 0.42
CYP3A4 P08684 1/20 0.41
HDAC3 O15379 2/20 0.41
HDAC4 P56524 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC7 Q8WUI4 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC10 Q969S8 2/20 0.41
HDAC11 Q96DB2 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC9 Q9UKV0 2/20 0.41
HDAC5 Q9UQL6 2/20 0.41
GAPDH P04406 1/20 0.40
PIK3CA P42336 3/20 0.39
MTOR P42345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25567580 0.87 ADORA2A (0.46) LMNAMAPTALDH1A1ROCK2ADORA2A
SCHEMBL14104064 0.85 CYP1A2 (0.51) LMNAMAPTALDH1A1ADORA2ACYP3A4
SCHEMBL29395996 0.85 CYP1A2 (0.51) LMNAMAPTALDH1A1ADORA2ACYP3A4
SCHEMBL12112029 0.82 ADORA2A (0.40) LMNAMAPTALDH1A1ROCK2ADORA2A
SCHEMBL873954 0.81 LMNA (0.59) LMNAMAPTALDH1A1ROCK2ADORA2A
SCHEMBL30460177 0.79 PIK3CA (0.70) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL22287875 0.79 PIK3CA (0.70) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL14103869 0.78 RAB9A (0.47) MAPTALDH1A1PIK3CAMTORMEN1
SCHEMBL960250 0.78 PIK3CA (0.59) LMNAADORA2ACYP3A4PIK3CAMTOR
SCHEMBL259607 0.76 RAB9A (0.55) LMNAMAPTALDH1A1ADORA2AGAPDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812446-B1 PHARMACEUTICAL COMPOUNDS PIRAMED LTD (GB) 2015-11-18 EP disclosed
US-7872003-B2 Pharmaceutical compounds F. HOFFMANN-LA ROCHE AG (CH) 2011-01-18 US disclosed
US-7872003-B2 Pharmaceutical compounds F. HOFFMANN-LA ROCHE AG (CH) 2011-01-18 US disclosed
US-7872003-B2 Pharmaceutical compounds F. HOFFMANN-LA ROCHE AG (CH) 2011-01-18 US disclosed
US-20080207609-A1 Pharmaceutical compounds PLRAMED LIMITED (GB) 2008-08-28 US disclosed
US-20080207609-A1 Pharmaceutical compounds PLRAMED LIMITED (GB) 2008-08-28 US disclosed
US-20080207609-A1 Pharmaceutical compounds PLRAMED LIMITED (GB) 2008-08-28 US disclosed
EP-1812446-A1 PHARMACEUTICAL COMPOUNDS Piramed Limited (GB) 2007-08-01 EP disclosed
WO-2006046040-A1 PHARMACEUTICAL COMPOUNDS PIRAMED LIMITED (GB) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207609-A1 Pharmaceutical compounds PIK3CA, JAK2, PIK3R1 LMNA 4414/4885MAPT 2811/4885ALDH1A1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.